

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)



(10) International Publication Number
WO 2022/214606 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) C07D 413/14 (2006.01)
C07D 401/14 (2006.01) C07D 417/14 (2006.01)
C07D 405/14 (2006.01) C07D 471/02 (2006.01)
C07D 407/14 (2006.01) A61P 35/00 (2006.01)
C07D 409/14 (2006.01) A61K 31/506 (2006.01)

(21) International Application Number:

PCT/EP2022/059295

(22) International Filing Date:

07 April 2022 (07.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21167278.7 07 April 2021 (07.04.2021) EP

(71) Applicant: **TOLREMO THERAPEUTICS AG**
[CH/CH]; Hofackerstrasse 40b, 4132 Muttentz (CH).

(72) Inventors: **FABRITIUS, Charles-Henry**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttentz (CH). **HEKKING, Koen**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttentz (CH). **GRUBER, Dorothea**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttentz (CH). **FOLMER, Rutger**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttentz (CH). **FLÜCKIGER-MANGUAL, Stefanie**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttentz (CH). **BOHNACKER, Thomas**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttentz (CH). **SCHWILL, Martin**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttentz (CH). **SCHMITZ-ROHMER, Debora**; c/o TOLREMO Therapeutics AG, Hofackerstrasse 40b, 4132 Muttentz (CH).

(74) Agent: **MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH**; Dr. Eva Dörner, Elisenhof, Elisenstr. 3, 80335 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER

(57) Abstract: The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the present invention relates to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use as a medicament and to the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions for use in the treatment or amelioration of cancer. Optionally, the compounds of formula (I) or the salts, solvates, cocrystals, tautomers, or mixtures thereof or the pharmaceutical compositions are administered in combination with a second therapeutic agent, in particular an anti-cancer agent.



WO 2022/214606 A1